Literature DB >> 22047631

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.

Hugo Vanderstichele1, Mirko Bibl, Sebastiaan Engelborghs, Nathalie Le Bastard, Piotr Lewczuk, Jose Luis Molinuevo, Lucilla Parnetti, Armand Perret-Liaudet, Leslie M Shaw, Charlotte Teunissen, Dirk Wouters, Kaj Blennow.   

Abstract

BACKGROUND: Numerous studies show that the cerebrospinal fluid biomarkers total tau (T-tau), tau phosphorylated at threonine 181 (P-tau(181P)), and amyloid-β (1-42) (Aβ(1-42)) have high diagnostic accuracy for Alzheimer's disease. Variability in concentrations for Aβ(1-42), T-tau, and P-tau(181P) drives the need for standardization.
METHODS: Key issues were identified and discussed before the first meeting of the members of the Alzheimer's Biomarkers Standardization Initiative (ABSI). Subsequent ABSI consensus meetings focused on preanalytical issues.
RESULTS: Consensus was reached on preanalytical issues such as the effects of fasting, different tube types, centrifugation, time and temperature before storage, storage temperature, repeated freeze/thaw cycles, and length of storage on concentrations of Aβ(1-42), T-tau, and P-tau(181P) in cerebrospinal fluid.
CONCLUSIONS: The consensus reached on preanalytical issues and the recommendations put forward during the ABSI consensus meetings are presented in this paper.
Copyright © 2012 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22047631     DOI: 10.1016/j.jalz.2011.07.004

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  127 in total

1.  Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes.

Authors:  Mahesh N Samtani; Nandini Raghavan; Yingqi Shi; Gerald Novak; Michael Farnum; Victor Lobanov; Tim Schultz; Eric Yang; Allitia DiBernardo; Vaibhav A Narayan
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

2.  Biomarkers of neurodegeneration - not only Alzheimer's disease and not only cerebrospinal fluid: a guest-editor's introduction.

Authors:  Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2012-07       Impact factor: 3.575

3.  The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease.

Authors:  Sebastiaan Engelborghs; Nathalie Le Bastard
Journal:  Mol Diagn Ther       Date:  2012-06-01       Impact factor: 4.074

Review 4.  Body fluid biomarkers for multiple sclerosis--the long road to clinical application.

Authors:  Charlotte E Teunissen; Arjan Malekzadeh; Cyra Leurs; Claire Bridel; Joep Killestein
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

5.  A guide for measurement of circulating metabolic hormones in rodents: Pitfalls during the pre-analytical phase.

Authors:  Maximilian Bielohuby; Sarah Popp; Martin Bidlingmaier
Journal:  Mol Metab       Date:  2012-08-09       Impact factor: 7.422

6.  Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations.

Authors:  Marta Cosín-Tomás; Anna Antonell; Albert Lladó; Daniel Alcolea; Juan Fortea; Mario Ezquerra; Albert Lleó; Maria José Martí; Mercè Pallàs; Raquel Sanchez-Valle; José Luís Molinuevo; Coral Sanfeliu; Perla Kaliman
Journal:  Mol Neurobiol       Date:  2016-09-08       Impact factor: 5.590

Review 7.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

8.  High performance liquid chromatography determination of L-glutamate, L-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer's disease.

Authors:  Tommaso Nuzzo; Andrea Mancini; Mattia Miroballo; Alessia Casamassa; Anna Di Maio; Giorgia Donati; Giulia Sansone; Lorenzo Gaetani; Federico Paolini Paoletti; Andrea Isidori; Paolo Calabresi; Francesco Errico; Lucilla Parnetti; Alessandro Usiello
Journal:  Amino Acids       Date:  2021-02-22       Impact factor: 3.520

9.  Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.

Authors:  Ann Hake; Paula T Trzepacz; Shufang Wang; Peng Yu; Michael Case; Helen Hochstetler; Michael M Witte; Elisabeth K Degenhardt; Robert A Dean
Journal:  Alzheimers Dement       Date:  2015-04-24       Impact factor: 21.566

10.  Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid.

Authors:  Susan M Landau; Ming Lu; Abhinay D Joshi; Michael Pontecorvo; Mark A Mintun; John Q Trojanowski; Leslie M Shaw; William J Jagust
Journal:  Ann Neurol       Date:  2013-12       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.